Cannabinoid reference entry
CBG
CBG is a molecule, not an effect category
CBG means cannabigerol, a phytocannabinoid found in cannabis. It is separate from CBD and THC. Early work also placed CBG in plant-chemistry discussions about cannabinoid formation, but a CBG result on a product profile is still only a composition finding. It is not a reliable shortcut to appetite, alertness, pain, sleep or anxiety.
The first evidence is molecular and animal work
Brain-membrane experiments measured CBG activity at alpha-2 adrenoceptors and its interaction with 5-HT1A receptors. Other laboratory assays tested cannabinoids against transient receptor potential channels and endocannabinoid enzymes. These systems help describe molecular activity under defined conditions.
In a rat feeding experiment, CBG increased food intake and meal frequency in pre-satiated animals without the measured neuromotor effects in that study. That result does not establish treatment for poor appetite or cachexia in people.
Small human studies answer narrower questions
A 2024 double-blind crossover field trial gave CBG or placebo to healthy adults and measured acute anxiety, stress, mood and cognitive or motor outcomes. A 2025 randomised trial in veterans with sleep problems found no statistically significant difference from placebo on its main sleep-quality measure; that study also had substantial completion attrition. Neither study tested a UK prescribed cannabis product or a broad patient-treatment outcome.
CBG in the full product record
The CBG figure belongs with the batch, formulation and other cannabinoids. The Home Office treats product and controlled-constituent status as preparation-specific. A CBG line therefore cannot supply a legal conclusion, a treatment decision or a prediction about an individual response. The MCPH cannabinoid reference is the useful next stop when several named compounds appear together.
Related conditions
Sources
- Evidence that the plant cannabinoid cannabigerol is an alpha2-adrenoceptor agonist (cell/membrane pharmacology, 2010).
- Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats (animal research, 2016).
- Acute effects of cannabigerol on anxiety, stress, and mood (human randomised crossover study, 2024).
- Effect of Cannabigerol on Sleep and Quality of Life in Veterans (human randomised trial, 2025).
For a plain-English glossary explanation, read CBG.